our pipeline

Our product pipeline has been rapidly maturing and we plan to approach the the clinical phases with our high priority vaccines candidates. Our Zika Vaccine program is gaining momentum and will likely become high priority in the near future. Our COVID-19 Vaccine is advancing at high speed and could be ready to enter the clinical Ph. I within a few months if financing is secured.

Pipeline.gif

“UNIVERSAL” FLU VACCINE

Our Universal Flu Vaccine is based on VLPs assembled with Remodeled HA proteins displaying highly conserved subdominant epitopes able to elicit Broadly Neutralizing Antibody responses in Humans.

Advantages

  • Cross Protection against multiple influenza strains.

  • Reduced frequency of immunization (longer protection).

  • Improved production Planning (manufacturing, storage and distribution).

  • Preliminary pre-clinical studies show that some of our VLP constructs induced antibodies in animal models able of neutralizing the homologous and heterologous virus strains.

“INHALED POWDER” VACCINES

“Shelf-Stable, Self-Inhaled, Powderized” VLP Vaccines.

TechnoVax and MannKind Corp. have combined their respective technologies to create a Powder Formulation of VLP Influenza Vaccine for Intrapulmonary Self-Delivery by Inhalation.

No refrigeration is required, and because it is potentially self-administered public exposure is limited. In the event of an emerging pandemic the vaccine could be easily distributed to the population, greatly reducing the spread of the virus!

Advantages

  • Extended Shelf Life and Elimination of Cold Chain results in improved distribution costs and inventory management.

  • Best Route of Immunization (mucosal surface – respiratory tract)

  • Increased Patient Acceptance (inhaled vs. injection)

“SEASONAL TETRAVALENT” INFLUENZA VLP VACCINE

The tetravalent flu VLP vaccine incorporates an additional B antigen to those recommended by the WHO, thus broadening vaccine protection.

Advantages:

  • Reduced manufacturing steps, time and costs.

  • Protects against multiple influenza virus strains.

  • Increased efficacy by targeting multiple viruses.

RSV VACCINE

Respiratory Syncytial Virus (RSV) is the most important cause of lower respiratory tract infection (LRI) in infants, children and the elderly worldwide:  RSV affects 64 million people and claims the lives of 160,000 yearly. In the USA only, RSV is responsible for about 100,000 infant and 175,000 elderly hospitalizations leading to the death of 14,000 elderly patients. There is no vaccine currently available.